GHCM
AKRO

Glen Harbor Capital Management’s Akero Therapeutics AKRO Stock Holding History

Glen Harbor Capital Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$17K Hold
748
– – ﹤0.01% 1304
2019
Q2 		$14K Buy
+748
New +$14.2K ﹤0.01% 1311

Other funds holding AKRO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Glen Harbor Capital Management's AKRO Position: Q3 2019 in Review

Glen Harbor Capital Management held its Akero Therapeutics (AKRO) position steady in Q3 2019 at 748 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #1304.

Glen Harbor Capital Management first reported a position in AKRO in Q2 2019 and has held it in 2 quarters since. 54 funds tracked by Wall St. Rank hold AKRO as of Q3 2019.

  • Glen Harbor Capital Management held 748 shares of Akero Therapeutics worth $17K as of Q3 2019.
  • Glen Harbor Capital Management left its Akero Therapeutics share count unchanged in Q3 2019.
  • Akero Therapeutics made up ﹤0.01% of Glen Harbor Capital Management's portfolio in Q3 2019, its #1304 holding.
  • Glen Harbor Capital Management first reported a position in Akero Therapeutics in Q2 2019 and has held it in 2 quarters since.
  • 54 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2019.

Based on Glen Harbor Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.